BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/9/2015 5:57:00 PM | Browse: 1500 | Download: 2475
 |
Received |
|
2015-05-08 08:52 |
 |
Peer-Review Started |
|
2015-05-11 14:14 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2015-06-24 14:57 |
 |
Revised |
|
2015-07-06 21:26 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2015-08-19 15:09 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2015-09-02 15:16 |
 |
Articles in Press |
|
2015-09-02 15:16 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-11-03 15:50 |
 |
Publish the Manuscript Online |
|
2015-12-09 17:57 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin and In Sung Song |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dong Ho Lee, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam, Gyeonggi-do 463-707, South Korea. dhljohn@yahoo.co.kr |
| Key Words |
Helicobacter pylori; Moxifloxacin-based triple; Non-bismuth quadruple; Second-line; Eradication |
| Core Tip |
We aimed to compare 1-wk and 2-wk moxifloxacin-containing triple therapies after non-bismuth quadruple therapy failure for Helicobacter pylori (H. pylori) infection, especially in patients from a region known to be associated with a high resistance to antibiotics. The eradication rate of the 2-wk group was significantly higher than that of the 1-wk group (76.3% vs 56.7%, P < 0.05), and the incidence of side effects was similar. Thus, a 2-wk regimen may be a reasonable choice as second-line therapy for the eradication of H. pylori infection after non-bismuth quadruple therapy failure. |
| Publish Date |
2015-12-09 17:57 |
| Citation |
Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol 2015; 21(46): 13124-13131
|
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i46/13124.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i46.13124 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.